| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 技术授权(元) | - | 52,302,144.19 | - | 40,609,381.80 |
| 抗肿瘤类产品(元) | - | 3,505,586,692.42 | - | 1,977,509,270.21 |
| 对外授权收入(元) | - | - | 82,324.53 | - |
| 推广费收入(元) | 1,529,546.63 | - | 21,450,946.82 | - |
| 药品销售收入(元) | 2,372,212,845.71 | - | 1,554,925,368.87 | - |
| 其他(元) | 20,187.06 | - | - | - |
| 营业成本(元) | ||||
| 技术授权(元) | - | 35,445,528.69 | - | 1,999,473.56 |
| 抗肿瘤类产品(元) | - | 108,040,298.55 | - | 75,873,893.48 |
| 对外授权收入(元) | - | - | 32,428.70 | - |
| 推广费收入(元) | 15,237,701.83 | - | 17,864,882.04 | - |
| 药品销售收入(元) | 59,139,892.31 | - | 50,931,139.96 | - |
| 其他(元) | - | - | - | - |
| 毛利(元) | ||||
| 技术授权(元) | - | 16,856,615.50 | - | 38,609,908.24 |
| 抗肿瘤类产品(元) | - | 3,397,546,393.87 | - | 1,901,635,376.73 |
| 对外授权收入(元) | - | - | 49,895.83 | - |
| 推广费收入(元) | -13,708,155.20 | - | 3,586,064.78 | - |
| 药品销售收入(元) | 2,313,072,953.40 | - | 1,503,994,228.91 | - |
| 其他(元) | 20,187.06 | - | - | - |
| 毛利率(%) | ||||
| 技术授权(%) | - | 32.23 | - | 95.08 |
| 抗肿瘤类产品(%) | - | 96.92 | - | 96.16 |
| 对外授权收入(%) | - | - | 60.61 | - |
| 推广费收入(%) | -896.22 | - | 16.72 | - |
| 药品销售收入(%) | 97.51 | - | 96.72 | - |
| 其他(%) | - | - | - | - |
| 收入构成(%) | ||||
| 技术授权(%) | - | 1.47 | - | 2.01 |
| 抗肿瘤类产品(%) | - | 98.53 | - | 97.99 |
| 对外授权收入(%) | - | - | 0.01 | - |
| 推广费收入(%) | 0.06 | - | 1.36 | - |
| 药品销售收入(%) | 99.93 | - | 98.63 | - |
| 其他(%) | 0.00 | - | - | - |
| 毛利构成(%) | ||||
| 技术授权(%) | - | 0.49 | - | 1.99 |
| 抗肿瘤类产品(%) | - | 99.51 | - | 98.01 |
| 对外授权收入(%) | - | - | 0.00 | - |
| 推广费收入(%) | -0.60 | - | 0.24 | - |
| 药品销售收入(%) | 100.60 | - | 99.76 | - |
| 其他(%) | 0.00 | - | - | - |